Drugs / Benztropine
Benztropine
also known as
Benzatropina · Benzatropine · Benzatropine mesilate · Benztropine mesilate · benztropine mesylate · Benztropine methanesulfonate · Cobrentin · Cogentin · +2 more
Small molecule targets CHRM1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | COGENTIN | — | 1954-03-05 | fda.gov ↗ |
Trials 4
1952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00066937 | Nov 2002 → Jun 2008 | temporomandibular joint disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00000333 | May 2001 → Jan 2003 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06232473 | Jan 2024 → Nov 2027 expected | — | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00715377 | Jun 2007 → Dec 2011 | delusional disorder, schizoaffective disorder, schizophrenia, schizophreniform disorder | Centre for Addiction and Mental Health | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT00802100 Background | Dec 2008 → Sep 2009 | schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00457366 Comparator | May 2006 → Aug 2008 | — | University of Southern California | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benztropine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00802100 ↗ |
| Known as | Benzatropina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201203 ↗ |
| Known as | Benzatropine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201203 ↗ |
| Known as | Benzatropine mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201203 ↗ |
| Known as | Benztropine mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201203 ↗ |
| Known as | benztropine mesylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06232473 ↗ |
| Known as | Benztropine methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201203 ↗ |
| Known as | Cobrentin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201203 ↗ |
| Known as | Cogentin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00457366 ↗ |
| Known as | NK-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201203 ↗ |
| Known as | NSC-169913 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201203 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL1201203 ↗ |
| Modality | Small molecule | — CHEMBL1201203 ↗ |
| Route | Oral | “Benztropine Oral Product” NCT00066937 ↗ |
| Target | CHRM1 | “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL1201203 ↗ |